Company - Investors

In December 2006, MerLion finalised a round of US$ 30 million. This represented one of the largest rounds of drug discovery funding in Asia (ex-Japan).

MerLion’s revenues derive from discovery research fees, outlicensing payments and milestones.

MerLion has over US$100 million in potential milestone payments from its existing discovery agreements.

Current investors in MerLion include:

3i Group Investment LP, Aravis Venture I LP, Aurelia Private Equity, Brandenburg Capital, Bio*One Capital, Bioveda Capital, Commerce Ventures, JAFCO Asia Pacific, Lacuna SICAV Lacuna Apo Biotech Fund, Mitsubishi Corporation, Nomura Research and Advisory, Novartis Venture Fund, SBI Bio Life Science Investment, Temasek Holdings, United Overseas Bank, Venture Incubator and Zurcher Kantonalbank.